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Introduction
Starting in the 1980s, changes to funding policies and new, 
emerging scientific fields have been challenging the traditional 
relationship between academia and industry to include the transfer 
of technology from universities.1 The challenge for biotechnology 
developers is to overcome the divide between research outcomes and 
market adoption.
Biotechnology’s growth was accelerated by the policies of 
Reagan administration in regard to the transfer of technology from 
the academic sector to commercial sector. In 1982, for the first 
time, universities could take title to and could transfer to exclusive 
commercial rights to technologies developed under federal funding. 
For the industry, it overcame a severe limitation in the late 1970s 
only some 12,000 Ph.D.s were skilled at biotechnology, and the 
vast majority of these were entrenched in academia. For the start-up 
biotechnology entrepreneur, the early 1980s (and 1983 in particular) 
were an unprecedented era of capital availability. In any other era, with 
its surrounding circumstances, that expectation may not be workable.
Because biotechnology investments represented investments in 
research occurring at the molecular level, technical due diligence was 
difficult to verify, and there were no applicable valuation models at the 
outset of this industry. Thus, venture capitalists, investment bankers, 
and entrepreneurs dealt with almost totally unverifiable values. For 
the biotechnology entrepreneur, product opportunities may have 
stood in sharper relief than for electronics.2 The divide is in part due 
to the mission of technology transfer offices to focus on licensing IP, 
and the absence of interaction.3 The concept of the entrepreneur is 
problematic because by definition it aims to capture what is on the 
move and in a process of continuous change.4 
The many applications of biotechnologies 
Biotechnology is an area of science with enormous potential.5 
Cooperation and Development (OECD, 1989), biotechnology is the 
use of scientific and engineering principles (based on microbiology, 
genetics, biochemistry, chemical and biochemical engineering) to 
transform materials using biological agents (such as microorganisms, 
enzymes, animal or vegetable cells) with the aim of producing goods 
and services (OECD, 1989). Pharmaceuticals, new diagnostic kits, 
foods, chemical compositions, and new therapeutic methods are 
some examples of the goods obtainable, and environmental control 
and the treatment of effluents are among the services obtainable.6,7 
The use of biotechnology actually goes back thousands of years 
and can be considered to coincide with the beginning of agriculture: 
biotechnological type processes are used to obtain products known 
since ancient times, such as beer (produced by the fermentation 
of grains), yogurt and wine, just to name a few. In order to better 
understand the many uses of biological technologies made throughout 
history, the OECD has classified biotechnologies into three categories: 
Traditional biotechnologies, which are thousands of years old, such as 
fermentation; Modern biotechnologies, which were developed after 
the industrial revolution, such as the biological processes used to 
obtain vaccines, enzymes and hybrids; New biotechnologies, which 
have been developed since 1970, thanks to the discovery of DNA 
recombination and cell fusion.6 
The development of biotechnologies in the 
United States and Europe including Italy
The pioneering country was the United States where, starting 
from the early 1980s, small biotechnology companies (New 
Biotechnology Firms or NBFs) started up which developed the 
knowledge made available by genetic engineering and often made 
‘findings’ that could have industrial applications. They are actually 
small research companies offering particular services or working, 
for example, on the production of a certain protein or the discovery 
of a new pharmaceutical. They are usually unable to complete the 
whole innovative process and therefore they set up collaborative 
relationships with larger companies (Established Companies or 
ECs) and supply their own output to these companies. The American 
biotechnology industry is a real network made up of universities, 
public and private research centers, small biotechnological companies 
and large con- solidated companies all working in collaboration rather 
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than competition. The small companies are the real liaison between 
the academic world and the industrial world since they join ‘the 
scientific community (depository of knowledge) and the technological 
community (geared towards taking advantage of scientific knowledge 
for industrial use). In fact, most of these companies started up with 
the help of universities and their founders often continue to maintain 
close relationships with academic research institutes.6 
Biotechnologies represent one of the most significant emerging 
technologies, whose different applications can be used for the growth 
of knowledge-based industry.8 Even though there is a strong tradition 
of research in the pharmaceutical, chemical and food industries in Italy, 
the diffusion of the applications offered by biological technologies 
started taking place in Italy much later than in the United States and 
other European countries. This has led some experts to maintain that 
Italy has already missed the ‘train of biotechnologies’ (OPES, 2001). 
There are normative, institutional, cultural, and financial reasons for 
the late start of the development of the biotechnology industry in 
Italy. As far as the institutional aspect is concerned, in our country, 
as opposed to what has happened in other European countries (e.g. 
Germany), there has been a total lack of policies specifically aimed 
at supporting both research in the field of biotechnology and the 
industrial development of these technologies. In fact, the initiatives 
carried out by the Italian State can be summed up in a series of 
programs (e.g. Piano Biotecnologie Applicate per la Ricerca Avanzata 
and Programma Biotecnologie e Biostrumentazione) managed mostly 
by the academic world and, therefore, actually quite detached from the 
industry. There has basically been no process of knowledge transfer 
from universities to industries and, consequently, the phenomenon of 
academic spin offs, which is so widespread in the United States, has 
not taken place in Italy.5
The normative system has not helped improve this situation either, 
e.g. the complicated and often excessively bureaucratic norms which 
regulate the relationships between academic institutions and the 
industry and the limited protection guaranteed by patents. In addition 
to these difficulties, there is also the problem of finding venture capital. 
In fact, in Italy there is no structured system of venture capital which 
makes it possible to supply the financial resources needed to support the 
setting up of start up companies and the growth of the biotechnology 
industry segment in general. Therefore, even though there is a good 
level of scientific-technological knowledge and competencies in Italy 
(Gambardella, 1996), above all in the pharmaceutical field, there have 
been very few small startups specialized in biotechnologies. In fact, 
it is the general opinion of academics that in Italy biotechnologies 
and their applications are mostly developed in large consolidated 
companies (ECs) and public research centers (Orsenigo, 2001).5,9 It 
has been estimated, with a low margin of error, that there are about 
100 biotechnology companies in Italy.5
Entrepreneurship
Entrepreneurship starts with an idea or vision, occurring along 
a spectrum beginning at incremental improvement of an existing 
product or service, to a new revolutionary technology that disrupts an 
existing industry.10
Role of universities in supporting academic 
entrepreneurship
The general mission of an academic institution is twofold: to 
advance scientific knowledge and to share this knowledge for the 
benefit of the society. This latter ambition typically comes in the 
form of training students who then spread out into different sectors 
hosting conferences, consulting and collaborating with public and 
private interests, and publishing research results. Often overlooked is 
the intellectual property (IP) patented by academicians and licensed 
to private industry, a form of information transfer that can have 
significant societal and economic impact (4). This arrangement can 
have numerous beneficiaries; principals, and shareholders benefit 
from the direct financial success of the product, while researchers 
see wider and more rapid adoption of their ideas (5) and concomitant 
academic recognition.11
Entrepreneurship starts with an idea or vision, occurring along 
a spectrum beginning at incremental improvement of an existing 
product or service, to a new revolutionary technology that disrupts 
an existing industry.12 Academic entrepreneurship refers to university 
researchers commercializing university research through new business 
enterprises (Figure 1).13
Figure 1 Possible sequence in business models of individual dedicated biotechnology firms.
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International entrepreneurship (IE) 
Research in the fields of entrepreneurship and international 
entrepreneurship has experienced explosive growth recently. 
International Entrepreneurship can be divided into three major types 
of IE research:
a) Entrepreneurial Internationalization, 
b) International Comparisons of Entrepreneurship and 
c) Comparative Entrepreneurial Internationalization.
Type A research includes thematic areas in which the 
primary focus of each paper is concerned with: Venture Type, 
Internationalization, Networks and Social Capital, Organizational 
Issues and Entrepreneurship. Type B research has three main thematic 
areas consisting of Cross-Country and Cross-Cultural comparisons of 
entrepreneurship and studies which compare both. Type C research 
is the most recent to emerge and consists of studies that compare 
entrepreneurial internationalization across countries or cultures.13,14
Business model’ for Biotech entrepreneurship
The term ‘business model’ is an abstract term. Some authors that 
studied biotechnology firms, for example Lim (2003) and Pavlou and 
Belsey (2005), discerned different types of business models but did 
not define the general term. Chesbrough and Rosenbloom (2002) 
did develop a useful definition of the business model, although not 
specific for biotechnology firms. According to them, the business 
model describes how the firm plans to make money and specifies the 
position of the firm in the value chain (Chesbrough and Rosenbloom, 
2002). This definition implies that the activities a firm is engaged in 
are embedded in its business model. This portfolio of activities is, 
by definition, broader than just the main revenue generating activities 
of a firm. The business model of a firm does, however, provide an 
indication of the expected main revenue generating activities of the 
firm in the future. The choice for a specific business model is an 
important strategic choice, as firms can use it to position themselves 
within an industry.15 L. Willemstein and her colleagues worked on 
business models of Dutch dedicated biotechnology firms (DBFs) that 
are active in the field of medical biotechnology.15 
Limiting factors on Biotech entrepreneur
A Different breed
The biotech entrepreneur is unique from all other entrepreneurs. 
The biotech entrepreneur must still possess the same attributes all 
other entrepreneurs do; those being independence, confidence, a desire 
to take the road less traveled, a passion for their work, the ability to 
work long hours, unrelenting persistence, and willingness to take 
risks. In addition, the biotech entrepreneur is usually an accomplished 
scientist, bioengineer, physician, or businessperson. Most often, but 
not always, they have a PhD, MD, MBA, or combination of these 
educational backgrounds. A biotech entrepreneur voluntarily leaves 
their comfortable world, and steps into an industry that carries 
uncertainties and risks unique to any other business. A biotech 
entrepreneur recognizes problems, but does not focus on them for 
long. This is strength of the biotech entrepreneur – but it can also be 
their downfall if not moderated.16 
Know the challenges: count the costs
There are many challenges that await the entrepreneur. A 
biotechnology.17 company is a melding of business and science, 
and thus it creates a business of scientific uncertainty. The product 
development process contains unpredictable biological and technical 
risks. These risks arise from a core technology based upon promising 
yet unproven science. Entrepreneurs must be prepared for an 
extraordinarily long product development timeframe.
For the biotech entrepreneur, these risks are in addition to ones all 
entrepreneurs in any business face, such as overstretched operational 
capacities, new market development issues, and challenges recruiting 
quality people, to name a few. By stepping into the shoes of a 
biotech entrepreneur, the magnitude and number of obstacles surpass 
those all other entrepreneurs face.17 Before undertaking a start-up 
biotechnology company, one should count the costs because the 
stakes are exceedingly high. By understanding the challenges before 
beginning, one will be better prepared to handle them when they arise. 
Many individuals seek to accomplish lofty goals, but when things get 
tough, their desire wanes. Accomplishing anything of great value 
requires a significant amount of time and effort. The amount of time 
and effort is proportional to the significance of the endeavor.17,18 
Personal costs
It is equally important to recognize the personal and family costs 
before starting down this path. The biotech entrepreneur should have 
a strong support system of family and close friends because their work 
will also impact these individuals. A support system is vital, because 
there will be times when their understanding, encouragement, and 
help (possibly even their money) is needed.16 Likewise in Europe, 
companies were founded around prestigious scientific institutions, 
such as the University of Cambridge, UK, which provided the 
academic background to establish biotech startups and spinoffs 
engaging researchers as founders.19
Four backgrounds of Biotech entrepreneurs
Academic entrepreneurship is a process in which a university 
professor starts a new firm to turn his1 breakthrough scientific 
discovery into commercially viable products.2 The form and function 
of firms’ scientific advisory boards and the responsibilities and 
benefits of the members of these boards, however, receive much less 
research attention.
The typical biotech entrepreneur who starts a company usually 
comes from one of four background types. Although individuals from 
any background can start a biotechnology company – so long as they 
have the ideas, skills, and motivation. Unfortunately, the odds for 
success are heavily weighed against anyone not from one of these 
categories. Each of these backgrounds comes with their own strengths 
and weaknesses. The four most common backgrounds of life science 
entrepreneurs include the following:
1. The Scientist/Physician/Bioengineer who comes from an 
academic institution (University, Research Foundation, Non-
profit Research Institute)
2. The Scientist/Physician/Bioengineer who comes from within 
the life science industry such as another biotechnology 
company
3. A Businessperson, such as a former executive in the life 
science, pharmaceutical or venture capital industry, who is 
not a Scientist/Physician/Bioengineer
4. A Core Group of Individuals that are spun off from another 
life science organization within the industry.16,20
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For the scientist: things vs. People
The largest majority of biotech entrepreneurs come from a 
scientific background, and this influences the things to which they 
gravitate. Fundamentally, a large percentage of scientists become 
scientists because they either enjoy or are more comfortable working 
with “things” (experiments) rather than “people.” This does not imply 
that scientists do not like people; it is just that they find the challenges 
and rewards of research more fulfilling, compared to the challenges 
and rewards of predominantly working with people. Ironically, a 
significant part of a biotech entrepreneur’s job requires that they work 
more with people rather than with experiments and science. As with 
any job there are skills that must be acquired in order to do what needs 
to be done whether one enjoys it or not.
For the businessperson: communication with scientists
The entrepreneur with an entirely business background has a 
different challenge to wrestle with than does the scientist. Individuals 
with business backgrounds have a difficult time appreciating the 
technical challenges of the science, and typically have trouble 
understanding why technology development takes so long. This gap 
can be disastrous for planning. Most businesspersons do not have the 
background to readily understand the limitations of a technology; as 
a result, they may be surprised by “unplanned” scientific problems, 
resulting in product development delays that translate into financial 
shortfalls. To them, it may not seem obvious why a scientist cannot 
just run an experiment once, get the results, and move on. It is critical 
that the businessperson learn as much as possible about scientific 
issues by asking questions of the scientists to gain appreciation of the 
technology and its limitations. 
First time entrepreneur, first time in business
Alternatives to consider before taking the leadership 
role
If a professor, physician, scientist, or bioengineer from an academic 
background is contemplating starting a biotechnology company, but 
unsure about the decision to lead the company, they may want to 
consider a few alternatives. There are several ways to participate in 
the entrepreneurial process without carrying the responsibility for the 
entire organization and its outcome. Each of these alternatives still 
provides valuable experience for participating in the entrepreneurial 
process and equips you better for a future entrepreneurial opportunity. 
Options include:
1. Take the position of Chief Scientific Officer or Chief Medical 
Officer in the new company and allow someone else more 
experienced to shoulder the major business and financing 
responsibilities for the organization.
2. Participate as a cofounder in getting the company started and 
then return to research or medical practice, while contributing 
in a role as a Scientific Advisory Board Member or Board 
Member.
3. Be the scientific founder, help establish the company, and 
possibly work to get seed funding with the idea of later 
recruiting an experienced CEO. Find out how well you do 
before deciding whether or not to continue in this role, or turn 
it over to someone with more experience.
Passion and vision
The most successful biotech entrepreneurs all possess these two 
components – they have a vision and passion about what they are 
doing. Entrepreneurial passion is not an emotional characteristic, but 
a driving desire to accomplish something they firmly believe in, and 
will do, no matter how difficult the challenge. Being a visionary is 
about:
1. Seeing something others don’t see
2. Communicating what they see in a way that inspires others 
to follow
Entrepreneurs should be sure they possess these characteristics if 
they are going to start a biotech company, because they will need them 
when they face the many challenges during company development. 
Also, potential investors will be looking for these characteristics 
because they know that they are essential to building a successful 
company.16
Learn new skills quickly
Regardless of how accomplished someone may be in their present 
career, they should not be fooled into believing this guarantees 
success as a biotech entrepreneur. Entrepreneurs need to learn new 
skills quickly or they will not be successful.16
Have the ability to speak two languages
Be a Multi-disciplined translator
A significant universal barrier to achieving success for a 
biotechnology company is the absence of a “multi-disciplined 
translator”. A multi-disciplined translator is a person who understands 
the marketing, financial, and business issues, but also understands 
the technical and scientific issues – and speaks both languages 
well. One of two scenarios is usually played out in biotech start-up 
organizations: The first, is where the entrepreneur without a technical 
background, cannot or does not want to understand the scientific 
issues and limitations. In this situation, the entrepreneur operates 
in a pseudo-environment where they believe the science operates 
in a certain way, but in reality it does not. The second situation is 
where the entrepreneur is a scientist who cannot, or will not, learn to 
communicate scientific issues in a way that the business and financial 
persons and investors can understand. They tend to go headlong into a 
discourse on issues that are of no interest to anyone except those with 
a technical mind.16
Be a negotiator
This may sound like an unusual topic for a biotech entrepreneur.
 Enlarge your circle of influence
It is important for a biotech entrepreneur to build a circle of influence 
by including many people they trust – these will be individuals from 
whom they can later seek help, advice, and assistance.16
On creativity and change
One of the strengths of a start-up biotechnology company is their 
ability to respond quickly to change. The biotech entrepreneur’s 
ability to respond to change is critical to the future success of the 
organization.16
Summary
Successful entrepreneurs possess a diverse list of characteristics 
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that add significance at various stages of their biotech career. They 
are multi-taskers, or as one serial entrepreneur put it – they must have 
“rapidly adaptive, serial, single-pointed, focused attention.” First time 
entrepreneurs who have started and built companies will point out that 
the qualities described herein are ones they all wish they had a good 
dose of early in their tenure. A biotech entrepreneur may not initially 
possess every skill required to lead a talented and diverse team to 
build a successful business, however, as with any skill set, most can 
be learned if the entrepreneur is willing. Once these skill sets are 
acquired and proficiency is gained, these entrepreneurs generally go 
on to start many other biotech companies. These serial entrepreneurs 
successively build upon each previous learning experience and become 
proficient at their work and at recognizing the critical components of a 
successful business opportunity.
Whether someone seeks to start or join a company at any stage of 
development, a good analogy for building a biotech company is to 
realize that every great architectural structure we see today was first 
conceived in someone’s mind. The Eiffel Tower was just a concept – a 
grand idea that existed many years before the first steel girder was 
ever set in place. During its inception, the visionaries encountered 
seemingly insurmountable challenges, and were faced with many 
reasons to quit. Some of the naysayers of this project voiced that it 
costs too much, the design cannot support its weight, and the land 
where it is to be erected is not solid. Through the perseverance of 
the Tower’s visionaries and their ability to communicate the vision 
effectively to others – they recruited a team that later solved the 
engineering, construction, financing, and political challenges. As a 
result, this monumental piece of architecture stands today. What is 
your vision? Communicate it frequently to others, and before you 
know it you will see a company established and growing through 
the efforts of diverse individuals, all joined together to accomplish 
something far greater than anyone can accomplish alone.
It will thus be of use to individuals with interests, both commercial 
and academic, in areas of applied biotechnology and biochemistry.
The academic literature offers plenty of evidence that innovation 
and entrepreneurship are strongly correlated to economic growth. 
Moreover, regions with high levels of research and development, 
patents, start-ups, and venture capital develop faster than other 
areas. The missing link for many regions is the component of 
entrepreneurship; it is the entrepreneur who brings fresh ideas forward, 
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